Yatharth Hospital & Trauma Care Services Limited

BSE:543950 Stock Report

Market Cap: ₹51.4b

Yatharth Hospital & Trauma Care Services Valuation

Is 543950 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543950 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 543950's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 543950's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543950?

Key metric: As 543950 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543950. This is calculated by dividing 543950's market cap by their current earnings.
What is 543950's PE Ratio?
PE Ratio39.8x
Earnings₹1.29b
Market Cap₹51.44b

Price to Earnings Ratio vs Peers

How does 543950's PE Ratio compare to its peers?

The above table shows the PE ratio for 543950 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.3x
523323 Kovai Medical Center and Hospital
28.5xn/a₹57.5b
ARTEMISMED Artemis Medicare Services
70.5x38.4%₹45.6b
HCG HealthCare Global Enterprises
123x48.2%₹70.2b
INDRAMEDCO Indraprastha Medical
27.1xn/a₹40.0b
543950 Yatharth Hospital & Trauma Care Services
39.8x28.9%₹51.4b

Price-To-Earnings vs Peers: 543950 is good value based on its Price-To-Earnings Ratio (39.8x) compared to the peer average (62.3x).


Price to Earnings Ratio vs Industry

How does 543950's PE Ratio compare vs other companies in the IN Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
523696 Fortis Malar Hospitals
2.1xn/aUS$11.99m
542918 Gian Life Care
4.9xn/aUS$2.24m
No more companies available in this PE range
543950 39.8xIndustry Avg. 45.3xNo. of Companies6PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 543950 is good value based on its Price-To-Earnings Ratio (39.8x) compared to the Indian Healthcare industry average (45.3x).


Price to Earnings Ratio vs Fair Ratio

What is 543950's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543950 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.8x
Fair PE Ratio61x

Price-To-Earnings vs Fair Ratio: 543950 is good value based on its Price-To-Earnings Ratio (39.8x) compared to the estimated Fair Price-To-Earnings Ratio (61x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 543950 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹599.60
₹742.50
+23.8%
5.4%₹790.00₹680.00n/a4
Nov ’25₹677.65
₹644.25
-4.9%
11.9%₹720.00₹517.00n/a4
Oct ’25₹563.75
₹644.25
+14.3%
11.9%₹720.00₹517.00n/a4
Sep ’25₹523.55
₹644.25
+23.1%
11.9%₹720.00₹517.00n/a4
Aug ’25₹453.85
₹606.33
+33.6%
11.0%₹689.00₹525.00n/a3
Jul ’25₹418.65
₹606.33
+44.8%
11.0%₹689.00₹525.00n/a3
Jun ’25₹414.35
₹593.33
+43.2%
8.7%₹650.00₹525.00n/a3
May ’25₹445.00
₹596.67
+34.1%
9.0%₹658.00₹527.00n/a3
Apr ’25₹424.65
₹596.67
+40.5%
9.0%₹658.00₹527.00n/a3
Mar ’25₹443.65
₹596.67
+34.5%
9.0%₹658.00₹527.00n/a3
Feb ’25₹381.60
₹541.50
+41.9%
3.4%₹560.00₹523.00n/a2
Jan ’25₹374.50
₹531.50
+41.9%
1.6%₹540.00₹523.00n/a2
Dec ’24₹390.30
₹531.50
+36.2%
1.6%₹540.00₹523.00n/a2
Nov ’24₹359.25
₹531.50
+47.9%
1.6%₹540.00₹523.00₹677.652

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies